Virtual Library
Start Your Search
C. Evans
Author of
-
+
P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.01-063 - Development of a Patient-Reported Outcome (pro) Assessment of Core Non-Small Cell Lung Cancer (NSCLC) Symptoms (ID 863)
09:30 - 09:30 | Author(s): C. Evans
- Abstract
Background:
Early stage lung cancer is largely asymptomatic; however, as the disease progresses, patients experience significant distress from their lung cancer symptoms. The assessment and monitoring of changes in NSCLC symptoms is increasingly important in clinical trials when making treatment comparisons between new therapies. The objective of this study was to capture the patient perspective on core symptoms of NSCLC in order to develop a new symptom measure for use in clinical trials.
Methods:
This was a non-interventional, cross-sectional qualitative study that consisted of conducting individual interviews with patients with a diagnosis of NSCLC who were either treatment-naïve or had already received surgery, chemotherapy, radiation, or targeted therapy. Patients aged ≥18 years with stage IIB-IV NSCLC took part in concept elicitation interviews to provide descriptions of NSCLC symptoms, including severity, frequency and development over time. Data were used to develop the items constituting the Symptoms in Lung Cancer (SILC) Questionnaire.
Results:
A total of 28 patients were recruited (17 treatment-naïve, 11 post-treatment) for concept elicitation interviews. In the treatment-naïve population, the most common spontaneously reported symptoms of NSCLC were cough (58.8%), shortness of breath (47.1%), chest pain (47.1%) and fatigue (29.4%). These symptoms were included in the initial 12-item version of the SILC. An additional 10 patients participated in cognitive interviews to ensure that the items were correctly interpreted, relevant, and disease-related (i.e., not treatment-related). Following cognitive interviews and analysis of data from treatment-naïve and post-treatment patients, the fatigue items were dropped after patients indicated that attributing a specific symptom to the underlying condition or treatment was challenging. The final draft of the 9-item SILC uses a 5-point verbal response scale (higher scores indicating greater severity/frequency), a 7-day recall period, and assesses 3 core symptom concepts: chest pain (severity and frequency), cough (severity and frequency), dyspnea (while lying down/sitting, standing, walking, carrying a light load and when walking up an incline).
Conclusion:
SILC is an easy-to-use and concise tool to assess the core symptoms of disease in NSCLC patients, and is in compliance with the FDA PRO Guidance (2009) document.
